What Is Cartalax?
Cartalax, also written Kartalax, is the name used for a synthetic three-amino-acid peptide, Ala-Glu-Asp or AED. It comes from the Russian short-peptide bioregulator programme and is associated with research on cartilage and connective tissue.
The clearest primary evidence is a 2023 laboratory study of ageing rat chondrocytes, the cells that maintain cartilage. Researchers measured proteins associated with cellular ageing, inflammation and cell death. The experiment did not test pain, movement, joint structure or osteoarthritis treatment in people.
Reviews from the same research network mention animal models and oral use in older patients, but the accessible reports do not describe a controlled clinical trial in enough detail to evaluate it. Cartalax is not an approved medicine.
What is Cartalax made from?
Its reported sequence is:
`Ala-Glu-Asp (AED)`
The residues are alanine, glutamic acid and aspartic acid. A tripeptide contains three amino-acid residues joined by two peptide bonds. Cartalax is also described as T-31 in some chemical records.
It differs from collagen, which is a large structural protein, and from cartilage-derived polypeptide complexes containing many molecules. Findings from an animal-tissue extract cannot automatically be assigned to one defined tripeptide.
The indexed literature often calls the material simply “AED peptide”. The Cartalax or Kartalax name is linked to AED mainly through the originating group's reviews and product terminology.
What is cartilage and why is repair difficult?
Articular cartilage is the smooth tissue covering the ends of bones inside a joint. Its extracellular matrix contains collagen and proteoglycans, large molecules that retain water and help cartilage tolerate compression.
Chondrocytes are the relatively sparse cells responsible for maintaining that matrix. Adult cartilage has little direct blood supply, and established damage can be difficult to reverse. A laboratory change in chondrocyte proteins therefore cannot be assumed to rebuild the organised, load-bearing tissue of a human knee or hip.
What did the chondrocyte study examine?
The 2023 study compared primary chondrocytes from the intervertebral discs of young and old rats. Primary cells are taken directly from tissue rather than maintained as a laboratory cell line for many years. Intervertebral discs sit between the bones of the spine and are not identical to articular cartilage in a knee.
Researchers studied the senescence-associated secretory phenotype, usually shortened to SASP. Cellular senescence is a state in which a stressed or aged cell stops dividing but remains biologically active. Senescent cells can release inflammatory signals that affect nearby tissue.
Older rat cells showed higher synthesis of p16, p21 and p53, proteins involved in cell-cycle control and stress responses. Tumour necrosis factor alpha and interleukin-1 alpha, inflammatory signalling proteins, were also higher, while Sirtuin 1 was lower.
AED and a cartilage polypeptide complex shifted these measurements towards the pattern seen in younger cultures. The abstract calls this normalisation. It does not report new cartilage formation, mechanical strength or recovery of a living joint.
Do these markers show cartilage rejuvenation?
No. p16, p21, p53, inflammatory cytokines and Sirtuin 1 are biomarkers, meaning measurable features used to study a biological process. They participate in many pathways and are not direct measures of cartilage thickness or function.
Reducing inflammatory markers in a dish might be useful mechanistic evidence, but a treatment must also reach the joint, remain intact, affect the right cells and improve outcomes without causing harm. None of those steps was established by this experiment.
What evidence exists for osteoarthritis?
Osteoarthritis is a whole-joint disease involving cartilage, bone, the joint lining, ligaments, muscles and pain-processing pathways. A 2023 review from the originating research network states that AED, called Kartalax, showed high efficacy in animal osteoarthritis models and after oral administration in older patients.
The review does not provide enough accessible clinical detail to assess those claims. A dependable trial report would state participant numbers, diagnostic criteria, random allocation, placebo or active comparison, treatment duration, prespecified outcomes, numerical results, withdrawals and adverse events.
No such indexed primary human trial was identified through October 2026. The review statement should not be treated as proof that Cartalax relieves pain, improves mobility or preserves joints.
What would evidence of cartilage regeneration require?
Regeneration means restoring organised tissue, not merely changing a cell marker. In a joint, researchers would need to show that new material contains the correct arrangement of type II collagen and proteoglycans, integrates with surrounding cartilage and withstands repeated compression.
Animal studies can use microscopy, biochemical measurements and mechanical testing. Human research may use magnetic resonance imaging to estimate cartilage structure, but imaging changes need careful interpretation. Arthroscopy, a procedure in which a small camera is placed inside a joint, can view the surface but is invasive and would not be justified solely to investigate an unproved supplement claim.
Clinical trials should also measure pain and function using validated scales. These outcomes can be influenced by expectation, activity and natural fluctuation, which is why random allocation and an appropriate comparison group matter. Structural change and symptom relief are related questions, but one does not guarantee the other.
The AED chondrocyte paper measured neither tissue regeneration nor joint outcomes. It is an early mechanism experiment.
Why are the review's human claims difficult to assess?
The review says AED was effective after oral administration in older people with osteoarthritis, but the accessible record does not give the information required to judge that statement. It does not identify a clearly retrievable primary trial with participant flow, baseline disease severity or a prespecified main outcome.
Without randomisation, groups can differ before treatment begins. Without masking, awareness of treatment can influence symptom reporting and assessment. Without a placebo or established-treatment comparison, improvement may reflect natural fluctuation, concurrent care or expectation.
The missing numerical results are equally important. A report should show the size of the change, variation between participants and whether the difference is large enough to matter in daily life. Adverse events and withdrawals must be included, not only favourable outcomes.
The claim is therefore not necessarily false, but it remains unverifiable from the accessible scientific record. That is not a dependable basis for presenting Cartalax as a human treatment.
Could AED survive oral administration?
Cartalax is only three amino acids long. The digestive tract contains acid and enzymes that break dietary proteins and peptides into smaller pieces. Intestinal cells can transport some dipeptides and tripeptides, so complete breakdown should not be assumed. Absorption must nevertheless be measured for the particular sequence and formulation.
A pharmacokinetic study could look for intact AED in blood over time and calculate its maximum concentration and exposure. Researchers would also need to establish whether it enters joint fluid or cartilage rather than simply disappearing into general amino-acid metabolism.
No well-described human study supplies those measurements. An oral-use claim cannot by itself establish that enough intact peptide reaches chondrocytes to reproduce a cell-culture experiment.
Does lowering inflammatory signalling mean less joint pain?
Tumour necrosis factor alpha and interleukin-1 alpha help coordinate inflammation. Their levels were among the measurements changed in the rat cells. Osteoarthritis involves inflammatory signalling, but it is not simply a high-cytokine condition.
Pain can arise from bone, joint lining, ligaments, muscles and the nervous system. Cartilage itself contains few pain-sensing nerves. A lower cytokine signal in cultured chondrocytes therefore cannot predict how much a person will hurt or move.
Approved anti-inflammatory medicines are supported by human studies of symptoms and harms. AED has not passed comparable testing. The laboratory result helps form a hypothesis, not a treatment conclusion.
Is cellular senescence always harmful?
Senescence can limit the division of damaged cells and contributes to wound responses. Problems may arise when senescent cells persist and release signals that disrupt surrounding tissue. Removing or altering these cells could have benefits, neutral effects or unexpected harms depending on timing and tissue.
The AED experiment reported movement in a panel of SASP-associated proteins. It did not show that senescent cells were selectively removed or restored to a young state. Describing the result as “rejuvenation” would add a conclusion the experiment did not test.
Longer studies would need to examine cell survival, matrix production, genomic stability and tissue function together. Moving one panel of biomarkers is not enough.
How does Cartalax differ from cartilage extracts and collagen products?
Cartilage polypeptide complexes contain a mixture of chains derived from animal tissue. Collagen products contain larger protein fragments and are usually studied as nutritional materials. Cartalax is intended to be one chemically defined tripeptide.
These materials have different composition, digestion, quality risks and evidence. A result obtained with the cartilage polypeptide complex in the 2023 cell experiment cannot be attributed automatically to AED, even when both shifted the same markers. Likewise, research on collagen supplements does not validate Cartalax.
This separation is especially relevant because reviews sometimes discuss the extract and synthetic peptide together. Readers should check which material was actually tested in each experiment.
What questions remain unanswered?
- Is intact AED absorbed after oral administration?
- Does it reach cartilage or joint fluid at a biologically active concentration?
- Are its cell effects reproducible outside the originating network?
- Does it increase properly organised cartilage matrix?
- Can it improve pain and function beyond placebo or usual care?
- What happens with repeated exposure, kidney impairment or other medicines?
- Are products bearing the Cartalax name chemically and microbiologically equivalent?
Until these questions are answered, Cartalax remains a laboratory research peptide rather than a clinically validated joint therapy.
Is evidence from cells classed as human evidence?
No. The clearest direct AED experiment used rat chondrocytes outside the body. Even a study using cultured human cells would remain laboratory evidence rather than a clinical trial.
A human treatment study requires people to receive a defined intervention under a documented protocol, with outcomes and adverse events recorded. Cartalax lacks an adequately reported study of that kind.
How was Cartalax developed?
| Period | Development |
|---|---|
| 1970s onward | Soviet researchers developed animal-tissue peptide preparations and proposed organ-associated biological effects |
| Late twentieth to early twenty-first century | Short synthetic sequences, including AED, were assigned to specific tissue-research programmes |
| 2000s | Russian patent and review literature described AED in relation to bone and cartilage metabolism |
| 2023 | A primary paper reported effects on ageing-associated markers in cultured rat chondrocytes |
| 2023 | A review referred to animal and older-patient use without publishing a fully assessable clinical trial |
| Current position | Laboratory research peptide without established human efficacy or Western regulatory approval |
This is not a conventional Phase I, II and III programme. No published Phase I study clearly defines initial human exposure, tolerability and pharmacokinetics.
How is Cartalax synthesised and checked?
AED can be made by solid-phase peptide synthesis. Protected alanine, glutamic acid and aspartic acid building blocks are coupled in the intended order while the chain remains attached to a resin. Protecting groups stop the acidic side chains from reacting in the wrong place. The product is then released, deprotected and purified.
Quality control should confirm sequence as well as molecular mass. Mass spectrometry, sequence-sensitive fragmentation and chromatography can help distinguish the intended chain from incorrectly joined or shortened material. Testing may also measure peptide content, related substances, counterions and water.
A regulated sterile investigational product requires additional controls for batch consistency, potency, bacterial endotoxins, particles, sterility and stability. A commercial label or purity claim does not establish those standards. This section is explanatory, not a production method.
What is known about absorption and safety?
No well-described human pharmacokinetic study establishes how much intact AED is absorbed, how long it circulates, whether it reaches cartilage or how it is cleared. Oral claims particularly require evidence because digestive enzymes can break peptides into smaller fragments and amino acids.
The human safety record is too limited to define common or serious adverse effects. Relevant research questions include immune reactions, kidney clearance, unintended effects on cell-cycle pathways and impurities in unverified material. These are uncertainties rather than confirmed reactions.
Osteoarthritis is common among older adults, who may also have kidney, cardiovascular or gastrointestinal illness and may take several medicines. A useful safety programme would examine interactions, repeated exposure and whether reduced kidney function changes clearance. None of this can be inferred from a short cell-culture experiment.
Product quality also matters. Bacterial endotoxins, residual synthesis chemicals, incorrect sequence and inaccurate peptide content can create risks unrelated to AED itself. These controls require validated testing rather than a purity number on a certificate.
Is Cartalax approved?
No. Cartalax is not approved by the FDA, MHRA or EMA for osteoarthritis, disc disease, joint injury or any other condition. It should not be presented as a substitute for diagnosis, physiotherapy, established medicines or surgery when clinically required.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Does AED affect ageing chondrocytes? | Rat cell culture | Selected protein markers changed |
| Does it regrow cartilage? | No direct structural evidence | Not established |
| Does it relieve osteoarthritis symptoms? | Inadequately reported review claims | Not established |
| Does it work in people? | No assessable controlled trial identified | Unknown |
| Is it safe in people? | No adequate safety study | Unknown |
| Is it approved? | No FDA, MHRA or EMA approval | No |
Frequently asked questions
What is Cartalax?
It is a synthetic three-amino-acid peptide associated with cartilage research.
What is its sequence?
Ala-Glu-Asp, abbreviated AED.
Is Cartalax the same as collagen?
No. Collagen is a much larger structural protein.
Does Cartalax regrow cartilage?
No study has established cartilage regrowth in a living human joint.
Does it treat osteoarthritis?
No adequately reported controlled human trial establishes symptom or structural benefit.
Were chondrocytes studied?
Yes. A study used cultured cells from young and old rats.
What is SASP?
It is a pattern of inflammatory and other molecules released by some ageing or stressed cells.
Can biomarker changes prove joint improvement?
No. Clinical outcomes such as pain, movement and joint structure must be studied directly.
Is Cartalax known to be safe?
No adequate human safety profile exists.
Is Cartalax approved?
It is not approved by the FDA, MHRA or EMA.
Sources
Research reviewed through October 2026.